Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.

ESMO open·2021
Same author

No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.

Diabetic medicine : a journal of the British Diabetic Association·2017
Same author

The impact of age and gender on papillary thyroid cancer survival.

The Journal of clinical endocrinology and metabolism·2012
Same author

Approach to the patient with advanced differentiated thyroid cancer.

European journal of endocrinology·2011
Same author

Not so fast on the thyroidectomy--response to Eloy, et al.

AJNR. American journal of neuroradiology·2010
Same author

Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.

The Journal of clinical endocrinology and metabolism·2009

Related Experiment Video

Updated: Jun 13, 2026

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
05:21

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay

Published on: September 13, 2024

Cytotoxic chemotherapy for differentiated thyroid carcinoma.

S I Sherman1

  • 1Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230-1402, USA. sisherma@mdanderson.org

Clinical Oncology (Royal College of Radiologists (Great Britain))
|May 11, 2010
PubMed
Summary

Systemic chemotherapy offers limited options for metastatic differentiated thyroid cancer. While doxorubicin shows some efficacy, newer agents like pemetrexed and improved clinical trial designs may offer better outcomes for patients.

More Related Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Jun 13, 2026

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay
05:21

Assessing Antibody-dependent, Cell-mediated Cytotoxicity in Cancer Cells using Antibody-Dependent Cell-Mediated Cytotoxicity Reporter Bioassay

Published on: September 13, 2024

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic differentiated thyroid carcinoma (DTC) presents treatment challenges, especially after standard therapies fail.
  • Systemic cytotoxic chemotherapy has historically shown limited efficacy and significant toxicity in metastatic DTC.
  • Previous studies struggled to identify effective regimens due to small patient cohorts and recruitment issues.

Purpose of the Study:

  • To review the current landscape of systemic chemotherapy for metastatic differentiated thyroid carcinoma.
  • To evaluate the efficacy and tolerability of established and novel chemotherapeutic agents.
  • To highlight the need for improved clinical trial strategies in DTC.

Main Methods:

  • Review of historical phase II studies and retrospective series on chemotherapy for metastatic DTC.
  • Analysis of the effectiveness and toxicity profiles of key chemotherapeutic agents, including doxorubicin and pemetrexed.
  • Discussion of challenges in clinical trial design and patient recruitment.

Main Results:

  • Doxorubicin is the most effective single agent but offers rare complete responses and considerable toxicity.
  • Newer agents, such as pemetrexed, show potential for improved benefit and tolerability.
  • Challenges in trial recruitment have historically limited the identification of effective treatments.

Conclusions:

  • Effective systemic chemotherapy options for advanced metastatic differentiated thyroid carcinoma remain limited.
  • Pemetrexed represents a potentially better-tolerated alternative to traditional agents.
  • Innovations in treatment approaches and clinical trial design, including early patient involvement, are crucial for advancing care.